© 2022 MJH Life Sciences and Pharmacy Times – Pharmacy Practice News and Expert Insights. All rights reserved.
© 2022 MJH Life Sciences™ , Pharmacy Times – Pharmacy Practice News and Expert Insights. All rights reserved.
October 27, 2021
Sacituzumab govitecan-hziy (Trodelvy) is indicated for the treatment of patients with triple-negative breast cancer who have received 2 prior therapies at minimum for metastatic disease.
September 24, 2021
Enfortumab vedotin-ejfv (Seagen; Padcev) is a first-in-class antibody-drug conjugate approved for patients with previously treated locally advanced or metastatic urothelial cancer.